Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 604

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1C
Chunk 604
---
 of record of our common stock. No cash dividends have been paid on the common
stock to date. A significant number of shares of our common stock are held in either nominee
name or street name brokerage accounts, and consequently, we are unable to determine the total number of beneficial owners of our common
stock.

Dividends

We have not paid any cash dividends
on our common stock to date and do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend to
retain earnings, if any, for the future operation and expansion of our business. Any determination to pay cash dividends in the future
will be at the discretion of our board of directors and will depend upon our results of operations, cash requirements, financial condition,
contractual restrictions, restrictions imposed by applicable laws and other factors that our board of directors may deem relevant

Unregistered
Sales of Equity Securities and Use of Proceeds

We have previously disclosed all
sales of securities without registration under the Securities Act of 1933, as amended.

Issuer
Purchases of Equity Securities

None

Item
6. [Reserved]

47

Item
7.

MANAGEMENT’S
DISCUSSION AND ANALYSIS OF

FINANCIAL
CONDITION AND RESULTS OF OPERATIONS

The
following discussion and analysis provide information which our management believes is relevant to an assessment and understanding of
our results of operations and financial condition. You should read the following discussion and analysis of our results of operations
and financial condition together with our financial statements and related notes and other information included elsewhere in this Annual
Report.

In
addition to historical financial information, this discussion contains forward-looking statements based upon our current expectations
that involve risks and uncertainties. Our actual results could differ materially from such forward-looking statements as a result of
various factors, including those set forth under “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements”
included elsewhere in this Annual Report. Additionally, our historical results are not necessarily indicative of the results that may
be expected for any period in the future.

Overview

We
are a pre-clinical-stage pharmaceutical company seeking to lead development in age-reversal science. The Company is focused on the development
of Telomir-1, a novel small molecule metal ion regulator, designed to lengthen the DNA’s protective telomere caps, which are
crucial in the aging process. The Company’s goal is to explore the potential of Telomir-1 starting with ongoing research